Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/24/25
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use DisorderPRNewsWire • 07/23/25
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31stPRNewsWire • 07/17/25
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate AffairsPRNewsWire • 07/08/25
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl UsersPRNewsWire • 06/19/25
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be MaintainedPRNewsWire • 06/02/25
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After PregnancyPRNewsWire • 05/01/25
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) InjectionPRNewsWire • 02/24/25
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings BeatBenzinga • 02/20/25